Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceuticals (RCE) secures a US patent for its antibiotic product RECCE 327 and antiviral formulation RECCE 529
- This is the company’s fourth of five patents to be granted, following China, Japan and Europe, with only Australia remaining
- The US is considered the largest and most influential pharmaceutical market in the world, valued at US$339 billion (around A$461 billion)
- On the market this morning, Recce was up 4.67 per cent and trading at $1.12 per share
Recce Pharmaceuticals (RCE) has been granted a US patent for its antibiotic product RECCE 327 and antiviral formulation RECCE 529.
This is the company’s fourth of five patent applications to be approved, following China, Japan and Europe, with only Australia remaining.
The US is considered the largest and most influential pharmaceutical market in the world, valued at US$339 billion (around A$461 billion).
Notably, the US market has developed and manufactured some of the world’s most innovative and best-selling drugs.
CEO James Graham is pleased with the anti-viral patent.
“Recce’s intellectual property portfolio continues to grow in line with our business strategy and the unprecedented global infectious disease crisis
before us,” Mr Graham said.
“We are thrilled to see that our Anti-viral patent was granted in the USA, the largest pharmaceutical market in the world; with yet further market-monopolies reinforcing the unique opportunities among a significant range of both bacterial and viral pathogens.”
Earlier this week, the company received a patent from the Chinese Patent Office.
On the market this morning, Recce was up 4.67 per cent and trading at $1.12 per share at 11:31 am AEST.
